inappropriately slow supraventricular rates will favor the emergence of ventricular ectopy. 18 Thus, SA node dysfunction may contribute to the ventricular arrhythmia (VA) in CPVT patients. Furthermore, because ectopic activity originating from the specialized conduction system can be suppressed by overdrive pacing or by administration of atropine, 19, 20 we hypothesized that accelerated sinus rates may be able to reset ventricular foci and thereby prevent premature ventricular focal activity. To test this hypothesis, we used vagolytic therapy with atropine and atrial pacing in 2 CPVT mouse models to investigate the antiarrhythmic potential of a catecholamine-independent heart rate (HR) acceleration preceding a β-adrenergic stress. To further evaluate the HR dependence of CPVT in humans, we screened a CPVT patient registry for individuals that were off antiarrhythmic drug therapy and reached >85% of their maximum-predicted HR during exercise testing.
Methods
Detailed methods are provided in the online Data Supplement.
Animal Studies
Animal use was in accordance with the National Institutes of Health guidelines and approved by the institutional animal care and use committee. Casq2 −/− and RyR2 R4496C/+ mice generation and in vivo characterization have been previously described. 10, 21 
Atropine Treatment Before ISO Challenge and Surface ECG Recording
Experiments were performed in a randomized crossover design. Surface ECGs were recorded from Casq2 −/− mice (n=15) and wildtype (WT) littermates (n=11), challenged with 3 mg/kg of isoproterenol (ISO) 8 minutes after injection of either vehicle (distilled water) or atropine (0.5 mg/kg). Arrhythmia incidence and arrhythmia score were determined in the atropine/ISO group and compared with the incidence and score of the same mice treated with vehicle/ISO.
Atrial Pacing in the Presence of ISO Challenge
Supraventricular overdrive stimulation was performed in anesthetized Casq2 −/− (n=19) and RyR2 R4496C/+ mice (n=9) using transesophageal atrial pacing. Atrial stimulation rates were selected to exceed the maximum intrinsic sinus rate achieved during catecholamine challenge (ie, 600 bpm for Casq2 −/− mice and 660 bpm for RyR2 R4496C/+ mice). The atrial overdrive pacing was maintained for the entire period the CPVT mice develop ventricular ectopy in response to the catecholamine challenge. Arrhythmia incidence and arrhythmia score were compared in the same mice challenged with ISO/caffeine in the presence or absence of atrial pacing.
Single Myocyte Studies
Ventricular myocytes were isolated from Casq2 −/− mice and loaded with Fura-2 AM for intracellular Ca measurements as previously described. 10 Myocytes were field-stimulated at increasing pacing rates (0.5-4 Hz) after adding ISO (1 µmol/L) to induce SCW. Ca fluorescence ratio (F ratio ) was recorded for 30 s at each pacing rate and incidences of SCW and triggered beats quantified.
CPVT Patient Data
To evaluate the HR dependence of CPVT in humans, we screened the entire registry of RyR2-mutation positive CPVT patients (N=162) of the Academic Medical Center (Amsterdam, the Netherlands) for exercise tests that were done before antiarrhythmic drug therapy was started. A total of 42 drug-naïve patients with VA were identified. Exercise testing was performed on a treadmill (standard or modified Bruce protocol) or a bicycle ergometer with a gradually increasing workload protocol. Patients exercised until exhaustion. To test our hypothesis that a fast supraventricular rhythm can overdrive VAs, only exercise tests from patients who reached at least 85% of their estimated maximum HR were used for the analysis (21 of 42 patients tested). Of these 21 patients, 3 developed VAs only at peak exercise and were excluded because the stress test was stopped before the suppression of arrhythmias could potentially occur by achieving a higher sinus rate. Thus, a total of 18 patients exercised beyond the onset of VAs and were included in the analysis.
Statistical Analysis
Data are presented as mean±SEM. Arrhythmia scores and number of ventricular premature beat (VPBs) were compared by means of the Mann-Whitney U test. Incidence of VA in the different groups was compared by Fisher exact test. A 2-tailed probability value <0.05 was considered statistically significant.
Results

Vagolytic Therapy Reduces the Incidence of VAs in a CPVT Mouse Model
Intraperitoneal injection of atropine induced a 15% increase of the intrinsic sinus rate in Casq2 −/− anesthetized mice compared with control injection of vehicle in the same mice (atropine 430±7 bpm versus vehicle 374±16 bpm, n=15; P<0.05, Figure 1A ). Eight minutes after atropine or vehicle injection, a catecholaminergic challenge with ISO was performed. As shown in Figure 1B , ISO induced a robust HR increase in both groups. Peak HR was higher in the atropine/ISO group (604±12 in atropine/ISO versus 565±19 in vehicle/ISO, n=15; P=0.09), whereas the magnitude of HR increase was comparable to that of the vehicle/ISO group.
Atropine pretreatment significantly reduced the VA score compared with vehicle/ISO controls (0.66±0.21 in atropine/ ISO versus 1.73±0.34 in vehicle/ISO; P<0.05, Figure 2A ). Of the 11 mice with significant ventricular ectopy during vehicle/ ISO treatment, 8 (73%) showed an improvement of their VA score, with 5 mice having complete VA suppression. Of the 7 mice with ISO-induced ventricular tachycardia (VT), 6 (86%) were free of VT after pretreatment with atropine ( Figure 2B ). Only 2 of 15 mice tested had a worsening of their VA score from 0 (no/sporadic VPBs) to 1 (frequent/bigeminal VPBs) with atropine/ISO ( Figure 2B ).
We then quantified the VA burden (VPBs/mouse). Mice pretreated with atropine displayed a reduction of ISO-induced VPBs compared with vehicle-treated mice (20±7 in atropine/ ISO versus 51±17 in vehicle/ISO, n=15; Figure 1B ). Furthermore, the incidence of VPBs peaked before the peak of sinus HR was reached ( Figure 1B ). In other words, VPBs were suppressed as the sinus HR rose further ( Figure 1B) . Interestingly, the same dose of atropine (0.5 mg/kg) did not significantly alter the sinus HR in anesthetized WT mice (427±10 bpm at baseline versus 432±16 bpm 8 minutes after atropine injection, P=0.7). Together with the observation that Casq2 −/− mice displayed a slower basal sinus HR compared with WT mice (388±8 bpm in Casq2 −/− versus 427±10 bpm in WT; P<0.05), this result indicates that vagal stimulation contributed to the sinus bradycardia of Casq2 −/− mice.
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Atrial Pacing Prevents VAs in Casq2 −/− Mice
To control for possible confounding effects by atropine (eg, direct pharmacological effects in the specialized conduction system and the ventricular myocardium), we next tested the effect of increasing supraventricular HR by transesophageal overdrive pacing in Casq2 −/− mice. Atria were paced at 10 Hz (600 bpm) to match the peak sinus rates obtained with a catecholaminergic challenge. Electrical capture of the atrium and appropriate atrioventricular node conduction was verified on ECG ( Figure 3A ). In the absence of catecholamine challenge, rapid atrial pacing (10 Hz, 30 s) induced ventricular ectopy in only 1 of 19 Casq2 −/− mice tested. Intermittent second degree atrioventricular block was observed in 3 of 19 mice during initial control pacing.
In response to ISO challenge, 11 of 19 (58%) Casq2 −/− mice developed ventricular ectopy ( Figure 3B ). Atrial overdrive pacing completely prevented VAs in 8 of those 11 mice (73%), with only 3 of 19 (15%) mice overall developing VAs (P<0.05; Figure 3B ). The VA score in the atrial pacing/ ISO group was significantly reduced compared with the ISO only control group (from 1.42±0.28 in ISO to 0.47±0.25 in atrial pacing/ISO; P<0.05; Figure 3C ). Overall, atrial overdrive pacing resulted in a 10-fold reduction in the number of ISO-induced VPBs (from 58±16 to 7±4 VPB/mouse; P<0.01; Figure 3D ).
Prolonged Atrial Pacing Prevents VAs in RyR2 R4496C/+ Mice
Because heterozygous mutations in the RyR2 gene are the most common cause of CPVT in patients, we next tested our hypothesis in a RyR2-linked CPVT mouse model, RyR2 R4496C/+ mice. 21 Compared with Casq2 −/− , RyR2 R4496C/+ mice displayed both a higher HR at baseline (384±13 in Casq2 −/− versus 472±12 in RyR2 R4496C/+ ; P<0.001) and a higher peak sinus rate after ISO challenge (555±17 in Casq2 −/− versus 653±10 in RyR2 R4496C/+ ; P<0.001). Unlike Casq2 −/− mice, RyR2 R4496C/+ did not display ventricular ectopy in response to ISO only (3 VPBs in 1/7 mice tested). Hence, we used a combination of caffeine (120 mg/kg) and ISO (3 mg/kg) as catecholamine challenge to induce arrhythmias.
Injection of ISO/caffeine induced a rapid HR increase in all mice (n=9) and VAs in 66% of them ( Figure 4A and Note that the HR increase after ISO injection is similar in both groups but it is significantly shifted upward in the atropine-treated mice. In both groups, the number of VPB/mouse/s peaks when the HR is still increasing. By the time the maximum HR is reached, the arrhythmias are almost completely suppressed, *P<0.05, n=15 mice; VT indicates ventricular tachycardia. February 15, 2013 4B). However, in contrast to Casq2 −/− mice, where ectopy appeared during the first few seconds of the HR upstroke, RyR2 R4496C/+ developed VAs on average 3.5±0.8 minutes after injection and the episodes lasted longer (7.1±0.8 minutes until VAs stopped). Interestingly, at the onset of ventricular ectopy, the HR in RyR2 R4496C/+ mice had already slowed down to 68.5±6.7% of the maximum HR reached ( Figure  4A ). Prolonged overdriving pacing (660 bpm for 10 minutes) successfully prevented VAs in all but 1 mouse and reduced the VA score (from 1.8±0.58 in ISO/caffeine to 0.11±0.11 in atrial pacing-ISO/caffeine; P<0.05) and the number of VPBs recorded (from 543±239 VPBs in ISO/caffeine to 0.55±0.55 VPBs in atrial pacing-ISO/caffeine; P<0.05) compared with the same mice treated with ISO/caffeine in the absence of atrial pacing ( Figure 4B , 4C, and 4D).
Overdrive Pacing Suppresses ISO-induced SCWs in Casq2 −/− Myocytes
To further investigate the underlying mechanism of arrhythmia suppression at fast HRs, we next tested the effects of progressively shorter diastolic interval in single myocytes of Casq2 −/− mice. In the presence of ISO (1 µmol/L), myocytes were field-stimulated at 0.5, 1, 2, 3, and 4 Hz. SCWs were present in ≈40% of Casq2 −/− paced at 0.5 and 1 Hz. Reduction of the diastolic interval by higher pacing frequencies progressively reduced the incidence of SCWs ( Figure 5 ). At 3 Hz, only 8% of Casq2 −/− myocytes developed SCWs, and complete prevention of SCWs was achieved with overdriving pacing at 4 Hz ( Figure 5 ). Taken together, consistent with our in vivo experiment, overdrive pacing prevents ISO-induced SCWs in CPVT myocytes.
Sinus Tachycardia Paradoxically Suppresses Arrhythmias in a Subpopulation of CPVT Patients
The exercise tests of 18 CPVT patients carrying a mutation in the RyR2 gene met our inclusion criteria and were therefore used for the analysis. Basal HR was 76±4 bpm. As expected, at the beginning of the stress test, patients did not develop ventricular ectopy. With increasing exercise, all 18 patients exhibited ventricular ectopy. Three of them displayed couplets or VT as their first VA, the other 15 patients had frequent VPBs and bigeminal VPBs first. In 86% of the latter group, VA complexity increased leading to couplets (13/15, 86%) and VT (6/15, 43%). HR at the onset of ectopic activity was variable ranging from 95 to 150 bpm (mean 128±4 bpm). The first VA appeared at 65% of peak HR as shown in Figure 6A . On reaching 87% of their maximum HR peak, all the patients had developed VAs. However, in 6 of 18 patients (33%), VAs subsided as their sinus HR further increased to 89%, 91%, 93% (in 2 patients), 95%, and 99% of their peak HR ( Figure  6A ). The most severe arrhythmic phenotype displayed in these 6 patients before sinus tachycardia took over was bigeminal VPBs in 1 patient, couplets in 4, and VT in 1 ( Figure 6B ). Taken together, we find VA suppression with increasing sinus tachycardia in a subset of CPVT patients. We next compared the HR response in responders (=VA suppression by exercise) and nonresponders (=no VA suppression). As shown in Table  1 , resting HR, HR at the beginning of arrhythmia, and HR increase during exercise were not significantly different in the 2 groups. There was a trend that responders exercised for a longer period of time and at a higher intensity (metabolic equivalent of task values) compared with nonresponders. 
Discussion
Main Findings
Sinus bradycardia 1, 2, 9, 10, 12, 14, 15 and sinatrial node dysfunction 16, 17, 22, 23 can be found in CPVT patients and CPVT mouse models. Here, we tested the hypothesis that augmenting supraventricular HRs prevents CPVT in vivo. We find that both vagolytic therapy (Figures 1 and 2) and atrial overdrive pacing (Figures 3 and 4) can suppress catecholamine-induced VA in Casq2 −/− and RyR2 R4496C/+ mice. Our in vitro studies confirm that reduction of diastolic interval suppresses ISO-induced SCW in isolated Casq2 −/− myocytes, thereby reducing the risk of DADs and triggered activity ( Figure 5 ). In addition, we observed that in a subset of CPVT patients, exercise-induced VAs were paradoxically suppressed as sinus HRs increased further with continued exercise (Figure 6 ).
Antiarrhythmic Effect of Vagolytic Treatment in a CPVT Mouse Model
Pretreatment with atropine, which blocks muscarinic receptors 24 and increases SA node firing rates, 25 not only significantly reduced the overall VA score and the number of VPBs compared with controls but also prevented the most severe triggered events (couplets and VTs). We hypothesize that the atropine-induced acceleration of the supraventricular pacemaker caused an upward shift of the entire HR response curve to ISO (Figure 1) . As a result, the diastolic intervals in the ventricular tissue is shorter at every HR, thereby reducing the likelihood that SCW and DADs reach threshold and triggered beats. It could be argued that during CPVT, mice can reach higher ventricular rates 26 than the fastest sinus rate obtained in atropine-treated mice (Figure 1 ). However, when VAs start usually with sporadic VPBs and bigeminy, the HR increase is still moderate (Figure 1 ). It is only as VA complexity worsens that the coupling time of ectopic beats progressively reduces until fast VT is triggered. We hypothesize that atropine-induced accelerated sinus rhythm may be sufficient to interrupt simple arrhythmias, such as sporadic VPBs and bigeminy, arresting the likely progression of these events in VT.
Moreover, it will take at least a few seconds for the ISOinduced signal transduction events to occur that promote SR Ca overload and triggered arrhythmias. 27 By the time these effects have taken place, vehicle-treated mice develop complex arrhythmias (8 seconds after ISO injection), whereas atropine-treated mice are protected possibly because of their higher HR and hence shorter diastolic interval. Our in vitro studies ( Figure 5 ) confirm that a reduction of diastolic interval suppresses ISO-induced SCW in isolated Casq2 −/− myocytes, thereby reducing the risk of DADs and triggered activity. We speculate that the reduction of diastolic interval might be particularly effective in the Purkinje cells of the conduction system. In fact, it has recently been shown that Purkinje cells are more prone to developing DADs than working ventricular myocytes 28 because of intracellular characteristics that increase the Ca handling dysregulation in these cells. 29 The data from the RyR2 R4496C/+ CPVT mouse model reported here also support our hypothesis. Compared with Figure 6 . Fast sinus rhythm suppresses ventricular arrhythmias in a subpopulation of catecholaminergic polymorphic ventricular tachycardia (CPVT) patients. A, Cumulative arrhythmia incidence as a function of sinus heart rate (HR). HR is expressed as a percentage of the maximum HR reached during the exercise test by each patient. When a patient experienced a ventricular arrhythmia, he or she entered the Kaplan-Meier curve. All patients developed arrhythmias during exercise; however, in 6 patients ventricular arrhythmias were suppressed when their sinus HR further increased nearing peak exercise (downward steps in the graph). B, Example of ECG recorded during a stress test. This patient displays the first arrhythmias at a HR of 102 bpm (ventricular premature beats [VPBs]) are marked by black arrows). With the progression of the exercise, arrhythmia complexity increases up to ventricular tachycardia (ECG panel 3). When his HR reaches 148 bpm (95% of his maximum HR), arrhythmias are suppressed for the remaining time of the exercise test (ECG panels 4 and 5). Casq2 −/− mice, RyR2 R4496C/+ mice have significantly higher resting HRs and a significantly bigger response to ISO (compare Figures 3 and 4 ), similar to Casq2 −/− mice pretreated with atropine, which are resistant to ISO challenge (Figure 1 ). In RyR2 R4496C/+ , VAs can only be induced after sensitizing the RyR2 channels with caffeine, and even then the ventricular ectopy occurs only when the intrinsic sinus rate drops <70% of its peak value (Figure 4 ). Other groups have also reported that unlike Casq2 −/− mice, RyR2 R4496C/+ do not exhibit spontaneous or exercise-induced VAs. 15 Pharmacological challenges that include the use of catecholamines and caffeine are always required to elicit arrhythmias in this model. 15, 30 Our data demonstrate that overdrive pacing was effective also against druginduced VAs in RyR2 R4496C/+ mice. Interestingly, atropine injection increased the sinus HR to a much greater extent in Casq2 −/− compared with WT mice. This result suggests that vagal tone contributes to the sinus bradycardia observed in Casq2 −/− mice, either because of increased vagal tone or increased responsiveness of the SA node to vagal stimulation. Because sinus bradycardia 1, 2, 12 and SA node dysfunction 16, 17, 22 are also observed in CPVT patients, it is conceivable that an impaired sinus rate response during exercise contributes to the exercise-induced ventricular ectopy in CPVT patients. Consistent with this hypothesis, we observed complete VA suppression as the HR further increased approaching its peak in a subgroup of patients with significant ventricular ectopy in the early stages of the exercise ( Figure 5 ). This occurred despite the fact that catecholamine-induced HR increase initially is accompanied by progression of VA complexity. 2 Although it is well recognized that ectopic ventricular automaticity can be reset by overdrive pacing, [31] [32] [33] it is still unexpected that sinus tachycardia could provide sufficient protection against clinical CPVT. A possible explanation is that the positive chronotropic effect of β-adrenergic stimulation during stress could paradoxically counterbalance the triggered activity simultaneously promoted by β-adrenergically-induced SR Ca overload. However, possibly because of the small number of patients and the heterogeneity of exercise test protocols used, we could not detect a significant difference in the rate of HR increase in the subset of patients with arrhythmia suppression compared with the rest (Table 1) . A prospective study on a larger population would be needed to clarify the relationship between HR increase and arrhythmia suppression in CPVT patients.
Antiarrhythmic Effect of Atrial Overdrive Pacing in CPVT
As important proof of principle, we found that atrial overdrive pacing almost completely prevented catecholamine-induced VA in both Casq2 −/− and RyR2 R4496C/+ mice (Figures 3 and 4) . Finding alternative treatment approaches is an important issue for CPVT patients because β-blockers, which are the current gold standard in CPVT treatment, are not fully protective in up to 30% of the patients. 34, 35 On the basis of our experimental results reported here, one might speculate that the negative chronotropic effect of β-blockers might contribute to treatment failure. In fact, by slowing SA node activity, β-blockers may suppress an intrinsic antiarrhythmic mechanism of the HR increase. In support of this hypothesis, recent work has shown that although β-blockers protect most CPVT patients from severe exercise-induced arrhythmias, they reduce the sinus HR threshold at which milder VAs start. 36 On the contrary, molecules that regulate the RyR2 open probability (such as flecainide, propafenone, and RyR2 inhibitors S107, JTV519) reduce the frequency of diastolic SR Ca waves and triggered beats. 13, [37] [38] [39] Consistent with this mechanism, flecainide increased the sinus HR threshold at which VAs were triggered clinically, while at the same time reducing the peak HR reached during exercise. 40 
Clinical Implications and Caveats
Although vagolytic therapy would be difficult to perform in CPVT patients because of systemic side effects, 41 overdrive atrial pacing could be performed in patients with dual chamber pacemakers or implantable cardioverter-defibrillators. In support of this concept is a recent clinical case report of the temporary overdrive suppression of bidirectional VT by a rapid atrial tachycardia in a young CPVT patient. 42 One concern is that increasing the HR will independently load the SR with Ca 43 and may promote the spontaneous Ca release events that trigger CPVT. We tested this hypothesis experimentally, and found only 1 instance where rapid atrial pacing induced ventricular ectopy. Our data in CPVT patients further demonstrate that at least 30% of CPVT tolerated very fast sinus rates with paradoxical suppression of VA. To what extent this finding is applicable to other CPVT patients remains to be determined. For example, the incidence of atrial tachyarrhythmia is increased in CPVT patients, 1, 17 and atrial fibrillation has been associated with triggering CPVT clinically. 44 Another important consideration is the site of overdrive pacing. Given that electric stimulation by the pacing lead may trigger the release of norepinephrine from sympathetic nerve terminals in the ventricle, 45 which would further exacerbate the ventricular automaticity, atrial pacing likely will be the preferable approach. In either case, atrial overdrive pacing will have to be tested in humans with CPVT to evaluate its safety and efficacy. If rapid atrial pacing is shown to prevent exercise-induced VT in CPVT patients, it may be feasible to automatically program high atrial rates during exercise using the rate response feature. 46 
Conclusions
We report that increasing supraventricular rates, either by vagolytic therapy or by atrial overdrive pacing, protected against catecholamine-induced VT in 2 different mouse models of CPVT. Likewise, clinically in a substantial portion of CPVT patients, VAs were suppressed at peak exercise. Taken together, these results suggest that overdrive atrial pacing should be explored as a possible therapy for preventing exercise-induced VT in treatment-refractory CPVT patients.
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